Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003588 · ClinicalTrials.gov registry record · Phase 1
Gene Therapy in Treating Patients With Ovarian Cancer
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00003588: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00003588 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003588, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
Phase I trial to study the effectiveness of gene therapy in treating patients with ovarian cancer that has not responded to previous treatment. Inserting the p53 gene into a person's cancer cells may improve the body's ability to fight cancer or make the cancer cells more sensitive to treatment.
Interventions
- BIOLOGICAL Ad5CMV-p53 gene
- PROCEDURE laparoscopic surgery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 1998-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003588
The ClinicalTrials.gov registry entry for NCT00003588 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ad5CMV-p53 gene is the first listed.
NCT00003588 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003588 about?
NCT00003588 is a clinical study titled "Gene Therapy in Treating Patients With Ovarian Cancer". Phase I trial to study the effectiveness of gene therapy in treating patients with ovarian cancer that has not responded to previous treatment. Inserting the p53 gene into a person's cancer cells may improve the body's ability to fight cancer or make the cancer cells more sensitive to treatment.
What is the current status of trial NCT00003588?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 1998-09.
What interventions are being tested in trial NCT00003588?
The interventions under investigation include: Ad5CMV-p53 gene (BIOLOGICAL), laparoscopic surgery (PROCEDURE).
Who is sponsoring clinical trial NCT00003588?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.